Nogo and Nogo receptor: Relevance to schizophrenia?

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 150-157

  Willi, Roman ^a,b,c   Schwab, Martin E ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Animal models; Development; Myelin; NgR; Nogo A; Plasticity; Risk factors; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; NOGO RECEPTOR; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; PAIRED IMMUNOGLOBULIN LIKE RECEPTOR B; PROTEIN NOGO A; RECEPTOR; UNCLASSIFIED DRUG;

BIPOLAR DISORDER; CHROMOSOME 19Q; CHROMOSOME 22Q; CHROMOSOME 2P; FRONTAL CORTEX; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; HUMAN; LATENT INHIBITION; MYELINATION; NERVOUS SYSTEM DEVELOPMENT; NOGO GENE; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; POINT MUTATION; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; GPI-LINKED PROTEINS; HUMANS; MYELIN PROTEINS; RECEPTORS, CELL SURFACE; SCHIZOPHRENIA;

EID: 84876333883     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.01.011     Document Type: Review

References (102)

1. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
2. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
3. Aston C., Jiang L., Sokolov B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 2004, 77:858-866.
4. Barley K., Dracheva S., Byne W. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr. Res. 2009, 112:54-64.
5. Bassett A.S., Chow E.W. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol. Psychiatry 1999, 46:882-891.
6. Bassett A.S., Chow E.W., AbdelMalik P., Gheorghiu M., Husted J., Weksberg R. The schizophrenia phenotype in 22q11 deletion syndrome. Am. J. Psychiatry 2003, 160:1580-1586.
7. Bassett A.S., Marshall C.R., Lionel A.C., Chow E.W., Scherer S.W. Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum. Mol. Genet. 2008, 17:4045-4053.
8. Benes F.M. Myelination of cortical-hippocampal relays during late adolescence. Schizophr. Bull. 1989, 15:585-593.
9. Beveridge N.J., Cairns M.J. MicroRNA dysregulation in schizophrenia. Neurobiol. Dis. 2012, 46:263-271.
10. Budel S., Padukkavidana T., Liu B.P., Feng Z., Hu F., Johnson S., Lauren J., Park J.H., McGee A.W., Liao J., Stillman A., Kim J.E., Yang B.Z., Sodi S., Gelernter J., Zhao H., Hisama F., Arnsten A.F., Strittmatter S.M. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J. Neurosci. 2008, 28:13161-13172.
11. Buffo A., Zagrebelsky M., Huber A.B., Skerra A., Schwab M.E., Strata P., Rossi F. Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured purkinje cell axons. J. Neurosci. 2000, 20:2275-2286.
12. Carletti F., Woolley J.B., Bhattacharyya S., Perez-Iglesias R., Fusar Poli P., Valmaggia L., Broome M.R., Bramon E., Johns L., Giampietro V., Williams S.C., Barker G.J., McGuire P.K. Alterations in white matter evident before the onset of psychosis. Schizophr. Bull. 2012, 38:1170-1179.
13. Chen J., Lipska B.K., Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry 2006, 59:1180-1188.
14. Chong S.Y., Rosenberg S.S., Fancy S.P., Zhao C., Shen Y.A., Hahn A.T., McGee A.W., Xu X., Zheng B., Zhang L.I., Rowitch D.H., Franklin R.J., Lu Q.R., Chan J.R. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1299-1304.
15. Chow E.W., Ho A., Wei C., Voormolen E.H., Crawley A.P., Bassett A.S. Association of schizophrenia in 22q11.2 deletion syndrome and gray matter volumetric deficits in the superior temporal gyrus. Am. J. Psychiatry 2011, 168:522-529.
16. Consortium I.S. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008, 455:237-241.
17. Covault J., Lee J., Jensen K., Kranzler H. Nogo 3'-untranslated region CAA insertion: failure to replicate association with schizophrenia and demonstration of marked population difference in frequency of the insertion. Mol. Brain Res. 2004, 120:197-200.
18. Craveiro L.M., Hakkoum D., Weinmann O., Montani L., Stoppini L., Schwab M.E. Neutralization of the membrane protein Nogo-A enhances growth and reactive sprouting in established organotypic hippocampal slice cultures. Eur. J. Neurosci. 2008, 28:1808-1824.
19. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003, 60:443-456.
20. Delekate A., Zagrebelsky M., Kramer S., Schwab M.E., Korte M. NogoA restricts synaptic plasticity in the adult hippocampus on a fast time scale. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2569-2574.
21. Dracheva S., Davis K.L., Chin B., Woo D.A., Schmeidler J., Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol. Dis. 2006, 21:531-540.
22. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., Haddad L., Mier D., Opitz von Boberfeld C., Raab K., Witt S.H., Rietschel M., Cichon S., Meyer-Lindenberg A. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
23. Felsky D., Voineskos A.N., Lerch J.P., Nazeri A., Shaikh S.A., Rajji T.K., Mulsant B.H., Kennedy J.L. Myelin-associated glycoprotein gene and brain morphometry in schizophrenia. Front. Psychiatry 2012, 3:40.
24. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008, 31:361-370.
25. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
26. Francks C., Tozzi F., Farmer A., Vincent J.B., Rujescu D., St Clair D., Muglia P. Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13. Mol. Psychiatry 2010, 15:319-325.
27. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24:527-533.
28. Gregorio S.P., Mury F.B., Ojopi E.B., Sallet P.C., Moreno D.H., Yacubian J., Tavares H., Santos F.R., Gattaz W.F., Dias-Neto E. Nogo CAA 3'UTR Insertion polymorphism is not associated with schizophrenia nor with bipolar disorder. Schizophr. Res. 2005, 75:5-9.
29. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4746-4751.
30. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt. 4):593-624.
31. Hirvonen J., van Erp T.G., Huttunen J., Aalto S., Nagren K., Huttunen M., Lonnqvist J., Kaprio J., Hietala J., Cannon T.D. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry 2005, 62:371-378.
32. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., Davis K.L. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 2003, 53:1075-1085.
33. Hsu R., Woodroffe A., Lai W.S., Cook M.N., Mukai J., Dunning J.P., Swanson D.J., Roos J.L., Abecasis G.R., Karayiorgou M., Gogos J.A. Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS One 2007, 2:e1234.
34. Huber A.B., Weinmann O., Brosamle C., Oertle T., Schwab M.E. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J. Neurosci. 2002, 22:3553-3567.
35. Jitoku D., Hattori E., Iwayama Y., Yamada K., Toyota T., Kikuchi M., Maekawa M., Nishikawa T., Yoshikawa T. Association study of Nogo-related genes with schizophrenia in a Japanese case-control sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:581-592.
36. Kano S., Nwulia E., Niwa M., Chen Y., Sawa A., Cascella N. Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neurosci. Res. 2011, 71:289-293.
37. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., Gos A., Nestadt G., Wolyniec P.S., Lasseter V.K., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7612-7616.
38. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 2010, 11:402-416.
39. Karoutzou G., Emrich H.M., Dietrich D.E. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol. Psychiatry 2008, 13:245-260.
40. Katsel P., Davis K.L., Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res. 2005, 79:157-173.
41. Kerns D., Vong G.S., Barley K., Dracheva S., Katsel P., Casaccia P., Haroutunian V., Byne W. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr. Res. 2010, 120:150-158.
42. Kirov G., Grozeva D., Norton N., Ivanov D., Mantripragada K.K., Holmans P., Craddock N., Owen M.J., O'Donovan M.C. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum. Mol. Genet. 2009, 18:1497-1503.
43. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J. Psychiatr. Res. 2007, 41:15-30.
44. Lee X., Yang Z., Shao Z., Rosenberg S.S., Levesque M., Pepinsky R.B., Qiu M., Miller R.H., Chan J.R., Mi S. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J. Neurosci. 2007, 27:220-225.
45. Lee H., Raiker S.J., Venkatesh K., Geary R., Robak L.A., Zhang Y., Yeh H.H., Shrager P., Giger R.J. Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J. Neurosci. 2008, 28:2753-2765.
46. Lee X., Hu Y., Zhang Y., Yang Z., Shao Z., Qiu M., Pepinsky B., Miller R.H., Mi S. Oligodendrocyte differentiation and myelination defects in OMgp null mice. Mol. Cell. Neurosci. 2011, 46:752-761.
47. Levinson D.F., Duan J., Oh S., Wang K., Sanders A.R., Shi J., Zhang N., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Kendler K.S., Freedman R., Dudbridge F., Pe'er I., Hakonarson H., Bergen S.E., Fanous A.H., Holmans P.A., Gejman P.V. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am. J. Psychiatry 2011, 168:302-316.
48. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 2002, 25:409-432.
49. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., Williams N.M., Schwab S.G., Pulver A.E., Faraone S.V., Brzustowicz L.M., Kaufmann C.A., Garver D.L., Gurling H.M., Lindholm E., Coon H., Moises H.W., Byerley W., Shaw S.H., Mesen A., Sherrington R., O'Neill F.A., Walsh D., Kendler K.S., Ekelund J., Paunio T., Lonnqvist J., Peltonen L., O'Donovan M.C., Owen M.J., Wildenauer D.B., Maier W., Nestadt G., Blouin J.L., Antonarakis S.E., Mowry B.J., Silverman J.M., Crowe R.R., Cloninger C.R., Tsuang M.T., Malaspina D., Harkavy-Friedman J.M., Svrakic D.M., Bassett A.S., Holcomb J., Kalsi G., McQuillin A., Brynjolfson J., Sigmundsson T., Petursson H., Jazin E., Zoega T., Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 2003, 73:34-48.
50. Li W., Zhou Y., Jentsch J.D., Brown R.A., Tian X., Ehninger D., Hennah W., Peltonen L., Lonnqvist J., Huttunen M.O., Kaprio J., Trachtenberg J.T., Silva A.J., Cannon T.D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18280-18285.
51. Liu H., Abecasis G.R., Heath S.C., Knowles A., Demars S., Chen Y.J., Roos J.L., Rapoport J.L., Gogos J.A., Karayiorgou M. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16859-16864.
52. Liu J., Juo S.H., Dewan A., Grunn A., Tong X., Brito M., Park N., Loth J.E., Kanyas K., Lerer B., Endicott J., Penchaszadeh G., Knowles J.A., Ott J., Gilliam T.C., Baron M. Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol. Psychiatry 2003, 8:333-342.
53. Marcus J., Dupree J.L., Popko B. Myelin-associated glycoprotein and myelin galactolipids stabilize developing axo-glial interactions. J. Cell Biol. 2002, 156:567-577.
54. Mathis C., Schroter A., Thallmair M., Schwab M.E. Nogo-a regulates neural precursor migration in the embryonic mouse cortex. Cereb. Cortex 2010, 20:2380-2390.
55. Matsushita H., Endo S., Kobayashi E., Sakamoto Y., Kobayashi K., Kitaguchi K., Kuroki K., Soderhall A., Maenaka K., Nakamura A., Strittmatter S.M., Takai T. Differential but competitive binding of Nogo protein and class i major histocompatibility complex (MHCI) to the PIR-B ectodomain provides an inhibition of cells. J. Biol. Chem. 2011, 286:25739-25747.
56. McCullumsmith R.E., Gupta D., Beneyto M., Kreger E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res. 2007, 90:15-27.
57. McGee A.W., Yang Y., Fischer Q.S., Daw N.W., Strittmatter S.M. Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 2005, 309:2222-2226.
58. Meng J., Shi Y., Zhao X., Guo S., Wang H., Zheng Y., Tang R., Feng G., Gu N., Liu H., Zhu S., He L. No association between the genetic polymorphisms in the RTN4R gene and schizophrenia in the Chinese population. J. Neural Transm. 2007, 114:249-254.
59. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog. Neurobiol. 2010, 90:285-326.
60. Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., Chang J., Thill G., Levesque M., Zhang M., Hession C., Sah D., Trapp B., He Z., Jung V., McCoy J.M., Pepinsky R.B. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005, 8:745-751.
61. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Miklasz S., Shea D., Mason J., Franklin R.J., Ji B., Shao Z., Chedotal A., Bernard F., Roulois A., Xu J., Jung V., Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 2009, 65:304-315.
62. Mingorance-Le Meur A., Zheng B., Soriano E., del Rio J.A. Involvement of the myelin-associated inhibitor Nogo-A in early cortical development and neuronal maturation. Cereb. Cortex 2007, 17:2375-2386.
63. Mitkus S.N., Hyde T.M., Vakkalanka R., Kolachana B., Weinberger D.R., Kleinman J.E., Lipska B.K. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr. Res. 2008, 98:129-138.
64. Montani L., Gerrits B., Gehrig P., Kempf A., Dimou L., Wollscheid B., Schwab M.E. Neuronal Nogo-A modulates growth cone motility via Rho-GTP/LIMK1/cofilin in the unlesioned adult nervous system. J. Biol. Chem. 2009, 284:10793-10807.
65. Novak G., Tallerico T. Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3'-UTR. Brain Res. 2006, 1120:161-171.
66. Novak G., Kim D., Seeman P., Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Mol. Brain Res. 2002, 107:183-189.
67. Pasaje C.F., Bae J.S., Park B.L., Park C.S., Kim B.J., Lee C.S., Kim J.W., Choi W.H., Shin T.M., Koh I.S., Choi I.G., Woo S.L., Shin H.D. Lack of association of the RTN4R genetic variations with risk of schizophrenia and SPEM abnormality in a Korean population. Psychiatry Res. 2011, 189:312-314.
68. Pernet V., Joly S., Christ F., Dimou L., Schwab M.E. Nogo-A and myelin-associated glycoprotein differently regulate oligodendrocyte maturation and myelin formation. J. Neurosci. 2008, 28:7435-7444.
69. Petrinovic M.M., Duncan C.S., Bourikas D., Weinman O., Montani L., Schroter A., Maerki D., Sommer L., Stoeckli E.T., Schwab M.E. Neuronal Nogo-A regulates neurite fasciculation, branching and extension in the developing nervous system. Development 2010, 137:2539-2550.
70. Pletnikov M.V. Inducible and conditional transgenic mouse models of schizophrenia. Prog. Brain Res. 2009, 179:35-47.
71. Raiker S.J., Lee H., Baldwin K.T., Duan Y., Shrager P., Giger R.J. Oligodendrocyte-myelin glycoprotein and Nogo negatively regulate activity-dependent synaptic plasticity. J. Neurosci. 2010, 30:12432-12445.
72. Rietkerk T., Boks M.P., Sommer I.E., de Jong S., Kahn R.S., Ophoff R.A. Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol. Psychiatry 2009, 14:353-355.
73. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
74. Roussos P., Katsel P., Davis K.L., Bitsios P., Giakoumaki S.G., Jogia J., Rozsnyai K., Collier D., Frangou S., Siever L.J., Haroutunian V. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch. Gen. Psychiatry 2012, 69:7-15.
75. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 2002, 296:692-695.
76. Schwab M.E. Functions of Nogo proteins and their receptors in the nervous system. Nat. Rev. Neurosci. 2010, 11:799-811.
77. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
78. Sinibaldi L., De Luca A., Bellacchio E., Conti E., Pasini A., Paloscia C., Spalletta G., Caltagirone C., Pizzuti A., Dallapiccola B. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum. Mutat. 2004, 24:534-535.
79. Syken J., Grandpre T., Kanold P.O., Shatz C.J. PirB restricts ocular-dominance plasticity in visual cortex. Science 2006, 313:1795-1800.
80. Takahashi H., Higuchi M., Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol. Psychiatry 2006, 59:919-928.
81. Takahashi N., Sakurai T., Davis K.L., Buxbaum J.D. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 2011, 93:13-24.
82. Tan E.C., Chong S.A., Wang H., Chew-Ping Lim E., Teo Y.Y. Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Mol. Brain Res. 2005, 139:212-216.
83. Tek C., Gold J., Blaxton T., Wilk C., McMahon R.P., Buchanan R.W. Visual perceptual and working memory impairments in schizophrenia. Arch. Gen. Psychiatry 2002, 59:146-153.
84. Tews B., Schönig K., Arzt M.E., Schneider M., Berger S., Willi R., Clementi S., Starkey M.L., Kempf A., Schwab M.E., Bartsch D. Transgenic Nogo-A deficient rats exhibit similar psychiatric endophenotypes as described for Nogo-A KO mice. Soc. Neurosci. Abstr. 2010, 36:62.12.
85. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
86. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
87. Voineskos A.N., de Luca V., Bulgin N.L., van Adrichem Q., Shaikh S., Lang D.J., Honer W.G., Kennedy J.L. A family-based association study of the myelin-associated glycoprotein and 2',3'-cyclic nucleotide 3'-phosphodiesterase genes with schizophrenia. Psychiatr. Genet. 2008, 18:143-146.
88. Wan C., Yang Y., Feng G., Gu N., Liu H., Zhu S., He L., Wang L. Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neurosci. Lett. 2005, 388:126-131.
89. Wang X., Chun S.J., Treloar H., Vartanian T., Greer C.A., Strittmatter S.M. Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J. Neurosci. 2002, 22:5505-5515.
90. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
91. White T., Magnotta V.A., Bockholt H.J., Williams S., Wallace S., Ehrlich S., Mueller B.A., Ho B.C., Jung R.E., Clark V.P., Lauriello J., Bustillo J.R., Schulz S.C., Gollub R.L., Andreasen N.C., Calhoun V.D., Lim K.O. Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr. Bull. 2011, 37:222-232.
92. Whitford T.J., Grieve S.M., Farrow T.F., Gomes L., Brennan J., Harris A.W., Gordon E., Williams L.M. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am. J. Psychiatry 2007, 164:1082-1089.
93. Willi R., Schwab M.E. Suppression of Nogo-A to enhance CNS repair. Cerebral Plasticity 2011, 367-382. MIT Press, Cambridge, MA. L.M. Chalupa, N. Berardi, M. Caleo, L. Galli-Resta, T. Pizzorusso (Eds.).
94. Willi R., Aloy E.M., Yee B.K., Feldon J., Schwab M.E. Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo-A. Genes Brain Behav. 2009, 8:181-192.
95. Willi R., Weinmann O., Winter C., Klein J., Sohr R., Schnell L., Yee B.K., Feldon J., Schwab M.E. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J. Neurosci. 2010, 30:556-567.
96. Wills Z.P., Mandel-Brehm C., Mardinly A.R., McCord A.E., Giger R.J., Greenberg M.E. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron 2012, 73:466-481.
97. Witthaus H., Brune M., Kaufmann C., Bohner G., Ozgurdal S., Gudlowski Y., Heinz A., Klingebiel R., Juckel G. White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophr. Res. 2008, 102:141-149.
98. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J.K., Malat J., Williams J.A., O'Tuama L.A., Snyder S.H., Kuhar M.J., Gjedde A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 234:1558-1563.
99. Xiong L., Rouleau G.A., Delisi L.E., St-Onge J., Najafee R., Riviere J.B., Benkelfat C., Tabbane K., Fathalli F., Danics Z., Labelle A., Lal S., Joober R. CAA insertion polymorphism in the 3'UTR of Nogo gene on 2p14 is not associated with schizophrenia. Brain Res. Mol. Brain Res. 2005, 133:153-156.
100. Xu B., Hsu P.K., Karayiorgou M., Gogos J.A. MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction. Neurobiol. Dis. 2012, 46:291-301.
101. Yang Y.F., Qin W., Shugart Y.Y., He G., Liu X.M., Zhou J., Zhao X.Z., Chen Q., La Y.J., Xu Y.F., Li X.W., Gu N.F., Feng G.Y., Song H., Wang P., He L. Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophr. Res. 2005, 75:11-19.
102. Yiu G., He Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 2006, 7:617-627.